welcome

We are glad to welcome you to our website

Government, and they may not be used for advertising or product endorsement purposes. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors.

Akerman ME, Pilch J, Peters D, Ruoslahti E. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Peptides as targeting elements and tissue penetration devices for nanoparticles. Girard JP, Springer TA. High endothelial venules (HEVs), specialized endothelium for lymphocyte migration. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. Fogal V, Zhang L, Krajewski S, Ruoslahti E. Pasqualini R, Ruoslahti E.

Tissue targeting with phage peptide libraries. Mol Psychiatry (1996) 1:423. Teesalu T, Sugahara KN, Ruoslahti E. Mapping of vascular ZIP codes by phage display.

Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Filamentous fusion phage, novel expression vectors that display cloned antigens on the virion surface.

Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III.

Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. Gerdin B, Lindeberg G, Ragnarsson U, Saldeen T, Wallin R.

Structural requirements for microvascular permeability-increasing ability of peptides. Studies on analogues of a fibrinogen pentapeptide fragment. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C.

Binding of a C-end rule peptide to the neuropilin-1 receptor, a molecular modeling approach. Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Aleman C, et al. Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor. Getz JA, Cheneval O, Craik DJ, Daugherty PS. Design of a Cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration.

Uniewicz KA, Fernig DG. Neuropilins, a versatile partner of extracellular molecules that regulate development and disease. Bagri A, Tessier-Lavigne M, Watts RJ. Neuropilins in tumor biology.

CCR-08-0563 CrossRef Full Text 29. Pellet-Many C, Frankel P, Jia H, Zachary I. Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Lohr M, Shaikh S, et al. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, et al.

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, et al. Targeting neuropilin-1 in human leukemia and lymphoma.